ESMO-GI 2020 - ESMO World Congress on Gastrointestinal Cancer (Virtual Meeting)
Jul 01 - Jul 04, 2020 | BarcelonaSpain
LARVOL is not affiliated with ESMO World Congress on Gastrointestinal Cancer (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 73 abstracts linked to Trials
[VIRTUAL] Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study
[VIRTUAL] Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC
[VIRTUAL] Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study
[VIRTUAL] KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
[VIRTUAL] Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
[VIRTUAL] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
[VIRTUAL] Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010
[VIRTUAL] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
[VIRTUAL] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)
[VIRTUAL] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
[VIRTUAL] Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
[VIRTUAL] The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
[VIRTUAL] Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial
[VIRTUAL] CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
[VIRTUAL] Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study